JP2019522024A5 - - Google Patents

Download PDF

Info

Publication number
JP2019522024A5
JP2019522024A5 JP2019503999A JP2019503999A JP2019522024A5 JP 2019522024 A5 JP2019522024 A5 JP 2019522024A5 JP 2019503999 A JP2019503999 A JP 2019503999A JP 2019503999 A JP2019503999 A JP 2019503999A JP 2019522024 A5 JP2019522024 A5 JP 2019522024A5
Authority
JP
Japan
Prior art keywords
transdermal delivery
salt
therapeutic agent
drug reservoir
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019503999A
Other languages
English (en)
Japanese (ja)
Other versions
JP7469879B2 (ja
JP2019522024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/044047 external-priority patent/WO2018022814A1/en
Publication of JP2019522024A publication Critical patent/JP2019522024A/ja
Publication of JP2019522024A5 publication Critical patent/JP2019522024A5/ja
Priority to JP2022025574A priority Critical patent/JP2022060428A/ja
Priority to JP2024000683A priority patent/JP2024019737A/ja
Application granted granted Critical
Publication of JP7469879B2 publication Critical patent/JP7469879B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019503999A 2016-07-27 2017-07-26 経口送達と生物学的に同等である薬物動態を有する経皮送達システム Active JP7469879B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022025574A JP2022060428A (ja) 2016-07-27 2022-02-22 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
JP2024000683A JP2024019737A (ja) 2016-07-27 2024-01-05 経口送達と生物学的に同等である薬物動態を有する経皮送達システム

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662367502P 2016-07-27 2016-07-27
US201662367542P 2016-07-27 2016-07-27
US62/367,542 2016-07-27
US62/367,502 2016-07-27
US201662423133P 2016-11-16 2016-11-16
US62/423,133 2016-11-16
US201762457794P 2017-02-10 2017-02-10
US62/457,794 2017-02-10
US201762504408P 2017-05-10 2017-05-10
US201762504391P 2017-05-10 2017-05-10
US62/504,408 2017-05-10
US62/504,391 2017-05-10
PCT/US2017/044047 WO2018022814A1 (en) 2016-07-27 2017-07-26 Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022025574A Division JP2022060428A (ja) 2016-07-27 2022-02-22 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
JP2024000683A Division JP2024019737A (ja) 2016-07-27 2024-01-05 経口送達と生物学的に同等である薬物動態を有する経皮送達システム

Publications (3)

Publication Number Publication Date
JP2019522024A JP2019522024A (ja) 2019-08-08
JP2019522024A5 true JP2019522024A5 (cg-RX-API-DMAC7.html) 2020-08-27
JP7469879B2 JP7469879B2 (ja) 2024-04-17

Family

ID=59593165

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019503999A Active JP7469879B2 (ja) 2016-07-27 2017-07-26 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
JP2022025574A Pending JP2022060428A (ja) 2016-07-27 2022-02-22 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
JP2024000683A Pending JP2024019737A (ja) 2016-07-27 2024-01-05 経口送達と生物学的に同等である薬物動態を有する経皮送達システム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022025574A Pending JP2022060428A (ja) 2016-07-27 2022-02-22 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
JP2024000683A Pending JP2024019737A (ja) 2016-07-27 2024-01-05 経口送達と生物学的に同等である薬物動態を有する経皮送達システム

Country Status (8)

Country Link
US (3) US20180028461A1 (cg-RX-API-DMAC7.html)
EP (1) EP3490559A1 (cg-RX-API-DMAC7.html)
JP (3) JP7469879B2 (cg-RX-API-DMAC7.html)
KR (1) KR102424270B1 (cg-RX-API-DMAC7.html)
CN (1) CN109789134A (cg-RX-API-DMAC7.html)
AU (2) AU2017302305A1 (cg-RX-API-DMAC7.html)
CA (1) CA3031944A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018022814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104603194B (zh) * 2012-07-17 2017-11-24 陶氏环球技术有限责任公司 包含有机液体稀释剂和低粘度纤维素醚的组合物
US10835499B2 (en) 2015-12-30 2020-11-17 Corium, Inc. Systems and methods for long term transdermal administration
CN109922796B (zh) 2016-06-23 2023-04-07 考里安有限责任公司 具有亲水和疏水域的粘合剂基质和治疗剂
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
JP7071330B2 (ja) * 2016-07-27 2022-05-18 コリウム, インコーポレイテッド 炭酸水素ナトリウムのin situ変換で促進されたアミン薬物の経皮送達
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
WO2019126531A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
KR102372630B1 (ko) * 2019-05-15 2022-03-14 주식회사 대웅제약 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제
WO2021003315A1 (en) * 2019-07-02 2021-01-07 Rowley Clifford T Transdermal patch providing improved permeability
US20230233480A1 (en) * 2019-10-24 2023-07-27 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of fingolimod
WO2021098791A1 (zh) * 2019-11-20 2021-05-27 成都康弘药业集团股份有限公司 一种含有美金刚的透皮贴剂
EP4362921A2 (en) * 2021-06-28 2024-05-08 Corium, LLC Corona discharge treated transdermal delivery system
JP2025509831A (ja) * 2022-03-14 2025-04-11 エーアールエックス,エルエルシー ある特定の第Xa因子阻害剤のための経皮送達系並びに関連するそれらの調製方法及び使用
KR20240146479A (ko) * 2023-03-29 2024-10-08 아이큐어 주식회사 고용량 도네페질 약물탑재 지속방출 경피흡수제제

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
NL134681C (cg-RX-API-DMAC7.html) 1966-04-26
US3546141A (en) 1966-08-08 1970-12-08 Mc Donnell Douglas Corp Phosphorus-nitrogen polymers and process
NL7305644A (cg-RX-API-DMAC7.html) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5252588A (en) 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
IE62597B1 (en) 1990-07-23 1995-02-08 Alza Corp Oral osmotic device for delivering nicotine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5123900A (en) 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
ATE194281T1 (de) 1994-09-14 2000-07-15 Minnesota Mining & Mfg Matrix für transdermale wirkstofffreisetzung
WO1996040087A2 (en) 1995-06-07 1996-12-19 Cygnus, Inc. Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
ES2191834T3 (es) 1996-10-24 2003-09-16 Alza Corp Agentes que facilitan la permeacion y destinados para composiciones, dispositivos y procedimientos de aporte transdermico de medicamentos.
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
ATE438418T1 (de) 2001-05-01 2009-08-15 Av Topchiev Inst Petrochemical Hydrogel-zusammensetzungen
CA2457011C (en) 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
NZ531404A (en) 2001-09-04 2006-03-31 Trommsdorff Gmbh & Co Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
US7273619B2 (en) 2002-01-17 2007-09-25 Samyang Corporation Transdermal composition of an antivomiting agent
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
CA2538856C (en) 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
AU2004316119B2 (en) 2003-10-22 2008-04-24 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies
AU2004292966A1 (en) 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
JPWO2005115355A1 (ja) 2004-05-28 2008-03-27 久光製薬株式会社 貼付製剤
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
ES2596809T3 (es) 2004-10-08 2017-01-12 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
MX2007007302A (es) 2005-01-11 2008-02-11 Teva Pharm Fine Chemicals Srl Proceso para la preparacion de clorhidrato de 1-amino-3,5-dimetiladamantano.
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
CN101460156B (zh) 2006-05-08 2011-06-08 帝国制药株式会社 抗痴呆药的经皮吸收制剂
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
US9248104B2 (en) 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
US20080107719A1 (en) 2006-11-08 2008-05-08 Sukhon Likitlersuang Transdermal drug delivery system
EP2638906A1 (en) 2006-12-01 2013-09-18 Nitto Denko Corporation Stabilized adhesive preparation containing donepezil
KR101408488B1 (ko) 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
AU2008275101B2 (en) 2007-07-10 2014-08-21 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
DE102008013701A1 (de) 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit stabilisierter Membran
AR074062A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
US20100178037A1 (en) 2009-01-12 2010-07-15 Te-Wei Chen Display apparatus, video generation apparatus, and method thereof
WO2010083035A2 (en) 2009-01-14 2010-07-22 Corium International, Inc. Transdermal administration of tamsulosin
JP5758290B2 (ja) 2009-05-01 2015-08-05 久光製薬株式会社 経皮吸収型製剤
AU2010309030B2 (en) 2009-10-21 2013-10-31 Teikoku Seiyaku Co., Ltd. Transdermally absorbable donepezil-containing preparation
CN102048678A (zh) 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
JP2012236773A (ja) * 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
CA2785639A1 (en) 2009-12-30 2011-07-07 Novartis Ag Melt extruded nicotine thin strips
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
ES2547888T3 (es) * 2010-04-28 2015-10-09 Hisamitsu Pharmaceutical Co., Inc. Preparación que contiene donepezilo absorbible por vía transdérmica
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
DE102010024105A1 (de) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20140370076A1 (en) 2010-06-30 2014-12-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
JP5699554B2 (ja) 2010-11-11 2015-04-15 富士通株式会社 ベクトル処理回路、命令発行制御方法、及びプロセッサシステム
TWI433904B (zh) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
US8673338B2 (en) 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
EP3054933A4 (en) * 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
PT3235494T (pt) 2014-12-18 2020-03-05 Icure Pharm Inc Preparação transdérmica contendo donepezilo como ingrediente ativo
CN108135860A (zh) 2015-06-22 2018-06-08 考里安国际公司 包含难溶性治疗剂的透皮粘合剂组合物
CN112843023A (zh) 2015-07-27 2021-05-28 久光制药株式会社 含有阿塞那平的贴剂的制造方法
US10835499B2 (en) * 2015-12-30 2020-11-17 Corium, Inc. Systems and methods for long term transdermal administration
CN105693556A (zh) 2016-03-01 2016-06-22 巴斯特医药科技(常州)有限公司 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片

Similar Documents

Publication Publication Date Title
US20220395469A1 (en) Transdermal drug delivery system for ketamine
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
JP6845162B2 (ja) ケタミン経皮送達システム
TWI244396B (en) A composition for topical application of methylphenidate and a pharmaceutical composition for treating attention deficit disorder and attention deficit/hyperactivity disorder
TWI241911B (en) Sustained release ranolazine formulations
KR102545649B1 (ko) 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법
AU2008267058C1 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
JP2023519959A5 (cg-RX-API-DMAC7.html)
KR100699958B1 (ko) 테르비나핀을 포함하는 제약학적 조성물 및 그의 용도
RU2007122410A (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda-рецептора, способ введения такого nmda-антагониста субъекту
EP2550961A1 (en) Solid preparation
US20120034276A1 (en) Solid preparation
JP2020536953A5 (cg-RX-API-DMAC7.html)
AU2011230778A1 (en) Solid preparation
WO2000064434A1 (en) Percutaneous preparations containing oxybutynin
JP2018500365A5 (cg-RX-API-DMAC7.html)
US20210251906A1 (en) Pregabalin extended-release formulations
JP2015526456A (ja) アミノアルキルナイトラートの延長放出(Extendedrelease)組成物
MX2010009917A (es) Composicion de liberacion modificada que comprende doxofilina.
TW201201806A (en) Sustained release preparation
JP2021506783A (ja) 経皮薬物送達の間にデポを作成するための方法
WO2005032441A1 (en) Transdermal delivery of oxybutynin in gel formulations
CN113194950B (zh) 早泄(pe)的治疗和预防
AU2012201640B2 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
KR20160141044A (ko) 실데나필 제어방출성 경구제제